Literature DB >> 19921495

A rare Asian founder polymorphism of Raptor may explain the high prevalence of Moyamoya disease among East Asians and its low prevalence among Caucasians.

Wanyang Liu, Hirokuni Hashikata, Kayoko Inoue, Norio Matsuura, Yohei Mineharu, Hatasu Kobayashi, Ken-Ichiro Kikuta, Yasushi Takagi, Toshiaki Hitomi, Boris Krischek, Li-Ping Zou, Fang Fang, Roman Herzig, Jeong-Eun Kim, Hyun-Seung Kang, Chang-Wan Oh, David-Alexandre Tregouet, Nobuo Hashimoto, Akio Koizumi.   

Abstract

BACKGROUND: In an earlier study, we identified a locus for Moyamoya disease (MMD) on 17q25.3.
METHODS: Linkage analysis and fine mapping were conducted for two new families in additional to the previously studied 15 families. Three genes, CARD14, Raptor, and AATK, were selected based on key words, namely, "inflammation", "apoptosis", "proliferation", and "vascular system", for further sequencing. A segregation analysis of 34 pedigrees was performed, followed by a case-control study in Japanese (90 cases vs. 384 controls), Korean (41 cases vs. 223 controls), Chinese (23 cases and 100 controls), and Caucasian (25 cases and 164 controls) populations.
RESULTS: Linkage analysis increased the LOD score from 8.07 to 9.67 on 17q25.3. Fine mapping narrowed the linkage signal to a 2.1-Mb region. Sequencing revealed that only one newly identified polymorphism, ss161110142, which was located at position -1480 from the transcription site of the Raptor gene, was common to all four unrelated sequenced familial affected individuals. ss161110142 was then shown to segregate in the 34 pedigrees studied, resulting in a two-point LOD score of 14.2 (P = 3.89 × 10(-8)). Its penetrance was estimated to be 74.0%. Among the Asian populations tested (Japanese, Korean, and Chinese), the rare allele was much more frequent in cases (26, 33, and 4%, respectively) than in controls (1, 1, and 0%, respectively) and was associated with an increased odds ratio of 52.2 (95% confidence interval 27.2-100.2) (P = 2.5 × 10(-49)). This allele was, however, not detected in the Caucasian samples. Its population attributable risk was estimated to be 49% in the Japanese population, 66% in the Korean population, and 9% in the Chinese population.
CONCLUSION: ss161110142 may confer susceptibility to MMD among East Asian populations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12199-009-0116-7) contains supplementary material, which is available to authorized users.

Entities:  

Year:  2009        PMID: 19921495      PMCID: PMC2824103          DOI: 10.1007/s12199-009-0116-7

Source DB:  PubMed          Journal:  Environ Health Prev Med        ISSN: 1342-078X            Impact factor:   3.674


  32 in total

1.  Worldwide distribution of moyamoya disease.

Authors:  Y Goto; Y Yonekawa
Journal:  Neurol Med Chir (Tokyo)       Date:  1992-11       Impact factor: 1.742

Review 2.  Moyamoya disease: current concepts and future perspectives.

Authors:  Satoshi Kuroda; Kiyohiro Houkin
Journal:  Lancet Neurol       Date:  2008-11       Impact factor: 44.182

3.  Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ('moyamoya' disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan.

Authors:  M Fukui
Journal:  Clin Neurol Neurosurg       Date:  1997-10       Impact factor: 1.876

4.  Parametric and nonparametric linkage analysis: a unified multipoint approach.

Authors:  L Kruglyak; M J Daly; M P Reeve-Daly; E S Lander
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

5.  Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain.

Authors:  J Suzuki; A Takaku
Journal:  Arch Neurol       Date:  1969-03

6.  Familial occurrence of moyamoya disease.

Authors:  T Yamauchi; K Houkin; M Tada; H Abe
Journal:  Clin Neurol Neurosurg       Date:  1997-10       Impact factor: 1.876

7.  Ultrastructural studies of cerebral arteries and collateral vessels in moyamoya disease.

Authors:  S Takebayashi; K Matsuo; M Kaneko
Journal:  Stroke       Date:  1984 Jul-Aug       Impact factor: 7.914

Review 8.  Moyamoya disease and moyamoya syndrome.

Authors:  R Michael Scott; Edward R Smith
Journal:  N Engl J Med       Date:  2009-03-19       Impact factor: 91.245

9.  Human leukocyte antigen in patients with moyamoya disease.

Authors:  M Aoyagi; K Ogami; Y Matsushima; M Shikata; M Yamamoto; K Yamamoto
Journal:  Stroke       Date:  1995-03       Impact factor: 7.914

10.  The cerebrospinal fluid in patients with moyamoya disease (spontaneous occlusion of the circle of Willis) contains high level of basic fibroblast growth factor.

Authors:  A Takahashi; Y Sawamura; K Houkin; H Kamiyama; H Abe
Journal:  Neurosci Lett       Date:  1993-10-01       Impact factor: 3.046

View more
  22 in total

1.  Genomewide association study identifies no major founder variant in Caucasian moyamoya disease.

Authors:  Wanyang Liu; S T M L D Senevirathna; Toshiaki Hitomi; Hatasu Kobayashi; Constantin Roder; Roman Herzig; Markus Kraemer; Maurits H J Voormolen; Pavlína Cahová; Boris Krischek; Akio Koizumi
Journal:  J Genet       Date:  2013-12       Impact factor: 1.166

2.  P.R4810K, a polymorphism of RNF213, the susceptibility gene for moyamoya disease, is associated with blood pressure.

Authors:  Akio Koizumi; Hatasu Kobayashi; Wanyang Liu; Yukiko Fujii; S T M L D Senevirathna; Shanika Nanayakkara; Hiroko Okuda; Toshiaki Hitomi; Kouji H Harada; Katsunobu Takenaka; Takao Watanabe; Shinichiro Shimbo
Journal:  Environ Health Prev Med       Date:  2012-08-10       Impact factor: 3.674

3.  The role of VEGF and KDR polymorphisms in moyamoya disease and collateral revascularization.

Authors:  Young Seok Park; Young Joo Jeon; Hyun Seok Kim; Kyu Young Chae; Seung-Hun Oh; In Bo Han; Hyun Sook Kim; Won-Chan Kim; Ok-Joon Kim; Tae Gon Kim; Joong-Uhn Choi; Dong-Seok Kim; Nam Keun Kim
Journal:  PLoS One       Date:  2012-10-12       Impact factor: 3.240

4.  Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development.

Authors:  Wanyang Liu; Daisuke Morito; Seiji Takashima; Yohei Mineharu; Hatasu Kobayashi; Toshiaki Hitomi; Hirokuni Hashikata; Norio Matsuura; Satoru Yamazaki; Atsushi Toyoda; Ken-ichiro Kikuta; Yasushi Takagi; Kouji H Harada; Asao Fujiyama; Roman Herzig; Boris Krischek; Liping Zou; Jeong Eun Kim; Masafumi Kitakaze; Susumu Miyamoto; Kazuhiro Nagata; Nobuo Hashimoto; Akio Koizumi
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

5.  Adult Moyamoya Disease: A Burden of Intracranial Stenosis in East Asians?

Authors:  Oh Young Bang; Sookyung Ryoo; Suk Jae Kim; Chang Hyo Yoon; Jihoon Cha; Je Young Yeon; Keon Ha Kim; Gyeong-Moon Kim; Chin-Sang Chung; Kwang Ho Lee; Hyung Jin Shin; Chang-Seok Ki; Pyoung Jeon; Jong-Soo Kim; Seung Chyul Hong
Journal:  PLoS One       Date:  2015-06-30       Impact factor: 3.240

6.  Moyamoya disease susceptibility gene RNF213 links inflammatory and angiogenic signals in endothelial cells.

Authors:  Kazuhiro Ohkubo; Yasunari Sakai; Hirosuke Inoue; Satoshi Akamine; Yoshito Ishizaki; Yuki Matsushita; Masafumi Sanefuji; Hiroyuki Torisu; Kenji Ihara; Marco Sardiello; Toshiro Hara
Journal:  Sci Rep       Date:  2015-08-17       Impact factor: 4.379

Review 7.  Single Nucleotide Polymorphism in Patients with Moyamoya Disease.

Authors:  Young Seok Park
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

8.  Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population.

Authors:  Zhiyuan Wu; Hanqiang Jiang; Lei Zhang; Xiao Xu; Xinju Zhang; Zhihua Kang; Donglei Song; Jin Zhang; Ming Guan; Yuxiang Gu
Journal:  PLoS One       Date:  2012-10-23       Impact factor: 3.240

9.  Frequency of the moyamoya-related RNF213 p.Arg4810Lys variant in 1,516 Korean individuals.

Authors:  Mi-Ae Jang; Sue Shin; Jong Hyun Yoon; Chang-Seok Ki
Journal:  BMC Med Genet       Date:  2015-11-20       Impact factor: 2.103

Review 10.  Intracranial atherosclerosis: current understanding and perspectives.

Authors:  Oh Young Bang
Journal:  J Stroke       Date:  2014-01-31       Impact factor: 6.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.